evaluate the pharmaceuticals company saxenda on how glp-1 works GLP-1 analogs, new trend in

2024NSFSC0576), and Post-Doctor Research Project, West China Hospital, Sichuan University (No

Why Employers Are Zeroing In On GLP-1s The numbers tell the story: 40% of US adults are living with obesity, with projections closer to 50% by 2030 Employers spend $6,472 more per year on employees with obesity than on healthy-weight employees across medical, productivity, disability, and workers comp Individuals who use GLP-1s can lose between 2.5% and 20% of their initial body weight when taking the medication as instructed Employers want to support prevention, not wait until employees are sicker to qualify for care

If coverage is genuinely unavailable, manufacturer direct-purchase channels and patient assistance programs run by Novo Nordisk and Eli Lilly are the next question to raise with a prescriber

[DOI] [PubMed] [Google Scholar] 31.Hayek A, Culler FL, Beattie GM, Lopez AD, Cuevas P, Baird A